Competitively-priced 0.014" workhorse guidewire designed for premium
performance in coronary and peripheral interventions – stainless
steel-nitinol core wires available in 190 cm and 300 cm lengths – with
enhanced trackability and torque control
WAYNE, Pa.--(BUSINESS WIRE)--Mar. 14, 2017--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
technologies for critical care and surgery, has announced 510(k)
clearance by the Food and Drug Administration and U.S. commercial launch
of the Spectre Guidewire.
The Spectre Guidewire is engineered with a smooth stainless
steel-to-nitinol dual-core transition that balances strength and
agility. It’s a 0.014" guidewire available in 190 cm and 300 cm lengths
with a distal hydrophilic coating and a proximal PTFE coating.
Approximately 70% of guidewires used in percutaneous coronary
interventions (PCIs) are considered workhorse wires and are used to
deliver catheters, balloons, stents, and other diagnostic and
therapeutic devices. As a workhorse wire, the Spectre Guidewire was
designed to be applicable to the majority of PCIs.
“We are excited to enter the large market for mainstream guidewires with
the introduction of Spectre, which offers high-end performance
characteristics at competitive prices in response to the demands of our
physician customers for more guidewire options,” said Chad Kugler, Vice
President of Research & Development of the Vascular Solutions division
of Teleflex. “Vascular Solutions designed Spectre with a proximal
stainless steel core that combines pushability with support for optimal
delivery and a distal nitinol core that is highly flexible and
kink-resistant for increased durability. We believe this design offers
an excellent combination of trackability and torque control.”
The Spectre Guidewire is intended for use in percutaneous procedures to
introduce and position catheters and other interventional devices within
the coronary and/or peripheral vasculature.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®,
and Weck® – trusted brands united by a common sense of
purpose.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA,
Pilling, Rusch, Spectre, and Weck are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries.
© 2017 Teleflex Incorporated. All rights reserved. MC-003147
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005152/en/
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836